Isolation and structural analysis of peptide mimotopes for the disialoganglioside GD2, a neuroblastoma tumor antigen

被引:34
|
作者
Föster-Waldl, E
Riemer, AB
Dehof, AK
Neumann, D
Brämswig, K
Boltz-Nitulescu, G
Pehamberger, H
Zielinski, CC
Scheiner, O
Pollak, A
Lode, H
Jensen-Jarolim, E [1 ]
机构
[1] Med Univ Vienna, Dept Pediat & Juvenile Med, Vienna, Austria
[2] Med Univ Vienna, Dept Pathophysiol, A-1090 Vienna, Austria
[3] Univ Saarland, Chair Bioinformat, D-6600 Saarbrucken, Germany
[4] Univ Saarland, Ctr Bioinformat, D-6600 Saarbrucken, Germany
[5] Med Univ Vienna, Dept Dermatol, Vienna, Austria
[6] Med Univ Vienna, Dept Internal Med 1, Vienna, Austria
[7] Univ Childrens Hosp, Charite Berlin, Berlin, Germany
[8] BioLife Sci, Vienna, Austria
关键词
ch14.18 monoclonal antibody; GD2; antigen; disialoganglioside; mimotope; antigen mimicry; modeling;
D O I
10.1016/j.molimm.2004.07.011
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The disialoganglioside GalAcbeta1-4(NeuAcalpha2-8NeuAcalpha2-3)Galbeta1-4Glcbetal-1Cer (GD2) is expressed on various tumors. including neuroblastoma, and was defined as a relevant turner antigen. The monoclonal anti-GD2 antibody 14.18 is widely used for diagnostic purposes in neuroblastoma, and in its mouse/human chimeric form (ch14.18) now enters passive immunotherapeutic regimens in phase II clinical trials. This study aimed to generate structural mimics of the 14.18 epitope of GD2. Therefore, we used the ch14.18 antibody for selecting immunoreactive GD2 peptide mimotopes from a decamer phage display library. In all, 13 GD2 peptide mimics could be determined by biopanning and their specificity was demonstrated by exclusive recognition by the ch14.18 antibody. Furthermore. their nature of being GD2 mimics and their degree of mimicry was confirmed by competition with the natural antigen. When performing a comparative visualization of the GD2 epitope and selected mimotopes using a three-dimensional computer modeling system (BALLView). we demonstrated fitting, of the GD2 molecule and the mimotopes in the antigen-binding pouch of a GD2 specific antibody. Moreover, the computer modeling argued for optimal affinity of the GD2 mimotopes. We thus provide evidence that the generation of GD2 peptide mimotopes is successful when using the neuroblastoma antibody ch14.18 for selection, and that this approach might offer a tool to develop a vaccination strategy against this malignant pediatric tumor. (C) 2004 Elsevier Ltd. All rights reserved.
引用
收藏
页码:319 / 325
页数:7
相关论文
共 50 条
  • [1] Disialoganglioside GD2 directed immunotherapy of neuroblastoma
    Lode, H.
    Siebert, N.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S75 - S75
  • [2] Induction of IgG antibodies against the GD2 carbohydrate tumor antigen by vaccination with peptide mimotopes
    Riemer, Angelika B.
    Foerster-Waldl, Elisabeth
    Braemswig, Kira H.
    Pollak, Arnold
    Zielinski, Christoph C.
    Pehamberger, Hubert
    Lode, Holger N.
    Scheiner, Otto
    Jensen-Jarolim, Erika
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 2006, 36 (05) : 1267 - 1274
  • [3] Structure based refinement of a humanized monoclonal antibody that targets tumor antigen disialoganglioside GD2
    Ahmed, Mahiuddin
    Hu, Jian
    Cheung, Nai-Kong V.
    [J]. FRONTIERS IN IMMUNOLOGY, 2014, 5
  • [4] Disialoganglioside GD2 loss following monoclonal antibody therapy is rare in neuroblastoma
    Kramer, K
    Gerald, WL
    Kushner, BH
    Larson, SM
    Hameed, M
    Cheung, NKV
    [J]. CLINICAL CANCER RESEARCH, 1998, 4 (09) : 2135 - 2139
  • [5] Targeting the disialoganglioside GD2 in neuroblastoma using a phage display derived oligopeptide
    Mueller, J.
    Vogt, S.
    Reichel, R.
    Fielitz, K.
    Mueller, S.
    Brandau, W.
    Schramm, A.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 : S295 - S295
  • [6] Disialoganglioside GD2 loss following monoclonal antibody therapy is rare in neuroblastoma
    Kramer, K
    Gerald, WL
    Kushner, BH
    Larson, SM
    Hameed, M
    Cheung, NKV
    [J]. MEDICAL AND PEDIATRIC ONCOLOGY, 2001, 36 (01): : 194 - 196
  • [7] Disialoganglioside GD2 and a novel tumor antigen:: Potential targets for immunotherapy of desmoplastic small round cell tumor
    Modak, S
    Gerald, W
    Cheung, NKV
    [J]. MEDICAL AND PEDIATRIC ONCOLOGY, 2002, 39 (06): : 547 - 551
  • [8] Age-dependent reference intervals in children for the disialoganglioside, GD2, a circulating tumor biomarker for the childhood cancer, neuroblastoma
    Busch, Christine M.
    Balis, Frank M.
    [J]. CLINICAL BIOCHEMISTRY, 2022, 101 : 1 - 4
  • [9] DISIALOGANGLIOSIDE GD2 IN HUMAN NEUROECTODERMAL TUMOR-CELL LINES AND GLIOMAS
    LONGEE, DC
    WIKSTRAND, CJ
    MANSSON, JE
    HE, X
    FULLER, GN
    BIGNER, SH
    FREDMAN, P
    SVENNERHOLM, L
    BIGNER, DD
    [J]. ACTA NEUROPATHOLOGICA, 1991, 82 (01) : 45 - 54
  • [10] A POTENT AND SPECIFIC IMMUNOTOXIN FOR TUMOR-CELLS EXPRESSING DISIALOGANGLIOSIDE GD2
    MUJOO, K
    REISFELD, RA
    CHEUNG, L
    ROSENBLUM, MG
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 1991, 34 (03) : 198 - 204